scholarly journals Refractive Outcomes of Patients Treated for Retinopathy of Prematurity

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Ayesha Khan ◽  
Kathryn Haider
Keyword(s):  
Laser Therapy ◽  
Refractive Error ◽  
Retinopathy Of Prematurity ◽  
High Myopia ◽  
Intravitreal Bevacizumab ◽  
Treatment Groups ◽  
Patient Demographics ◽  
Refractive Outcomes ◽  
Eye Exams ◽  
Lost To Follow Up

Background:  Retinopathy of prematurity (ROP) is a disease where the blood vessels in the eye fail to develop appropriately in infants born prematurely. Two effective treatments for ROP include laser photocoagulation therapy and intravitreal bevacizumab (IVB). Laser therapy has been linked to causing high myopia in children post-treatment. We hypothesize that patients treated with IVB alone or in combination with laser will have less myopia development than patients treated with laser therapy alone.  Methods:  Patient demographics, treatment details, refractive data at 6-9 months and 3-4 years, the occurrence of strabismus at 3 years, and the most recent vision data were collected from 133 ROP patients. Patients not treated at IU health and those lost to follow-up, or deceased before both eye exams, were excluded from the study. Quantitative analysis was used to compare the refractive error, strabismus, and vision outcomes between the three treatment groups. A linear regression model was used to analyze the relationship between the number of laser spots applied and refractive error.  Results:  Refractive outcomes at 6-9 months and 3-4 years, occurrence of strabismus, and vision outcomes were statistically similar between the three treatment groups. However, the laser group had the most occurrences of high myopia. We also observed a 0.002 unit decrease in refractive error, reported at 6–9-months, with each laser spot applied (p<0.001). This may be due to the influence of outliers because no significant relationship was seen at the 3–4 year exam.  Conclusion and Potential Impact:  There was no difference in outcomes among patients treated with IVB, laser, or a combination of both, with the exception of more myopic outliers in the laser-only group. We can therefore assume that ROP patients who have received one of these three treatments had developed differences in myopia independent of treatment modality. 

Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error Results

2013 ◽  
Vol 155 (6) ◽  
pp. 1119-1124.e1 ◽  
Author(s):  
Björn C. Harder ◽  
Frank C. Schlichtenbrede ◽  
Stefan von Baltz ◽  
Waldemar Jendritza ◽  
Bettina Jendritza ◽  
...  
Keyword(s):  
Refractive Error ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab

scholarly journals Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis

2017 ◽  
Vol 8 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Tomoaki Higashiyama ◽  
Sanae Muraki ◽  
Masahito Ohji
Keyword(s):  
Birth Weight ◽  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Gold Standard ◽  
Standard Treatment ◽  
Intravitreal Bevacizumab ◽  
Male Infant ◽  
Significant Benefit ◽  
Tunica Vasculosa Lentis

Background: Laser therapy has been the gold standard treatment for retinopathy of prematurity (ROP), while intravitreal bevacizumab (IVB) is reported to be of significant benefit for zone I ROP. A problem with laser therapy is that it is difficult to administer in ROP patients with severely dilated tunica vasculosa lentis and poor mydriasis. However, although IVB treatment has been performed in such severe ROP cases, only 1 report has discussed its usefulness. Case 1: A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. As visualization was poor and laser therapy could not be performed due to dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Case 2: A male infant was born with a birth weight of 698 g at 25 weeks’ gestation. As laser therapy could not be performed due to severely dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Conclusions: IVB is potentially more useful than laser therapy for the treatment of severe ROP with dilated tunica vasculosa lentis and poor mydriasis.

scholarly journals Refractive outcomes of laser-treated and non-laser-treated retinopathy of prematurity at Hospital Selayang: a 2-year retrospective review

2021 ◽  
Vol 3 (4) ◽  
pp. 210-222
Author(s):  
Aasiah Ahmad Sharifuddin ◽  
Fiona Lee Min Chew ◽  
Irina Effendi-Tenang ◽  
Amir Samsudin
Keyword(s):  
Retinopathy Of Prematurity ◽  
Retrospective Review ◽  
High Myopia ◽  
Laser Photocoagulation ◽  
Treated Group ◽  
Refractive Outcomes ◽  
Zone Ii ◽  
The Mean ◽  
The Difference

Objective: To compare the refractive outcomes of laser-treated and non-laser-treated retinopathy of prematurity (ROP) infant, at 2 years of age in Hospital Selayang.Methods: Retrospective review involving patients born between 2016 and 2018. They were divided into those who were treated with laser photocoagulation, and those who were observed. Laser treatment was given to infants with threshold and high-risk, pre-threshold disease. Refractive error was identified by cycloplegic refraction at 2 years of age.Results: There were 22 eyes from 11 infants in the laser-treated group, all of which had zone II ROP with plus disease; of these, four had stage 2 ROP and 18 had stage 3 ROP. There were 53 eyes from 28 patients in the non-laser-treated group. The mean birth weight for the laser-treated and non-laser-treated groups was 966.9 ± 92.6 g and 1019.3 ± 282.0 g, respectively (P = 0.398). Mean gestational age for the laser-treated and non-laser-treated groups was 28.2 ± 2.2 weeks and 27.7 ± 2.2 weeks, respectively (P = 0.390). At 2 years, the mean spherical equivalence for the laser-treated and non-laser treated groups was -0.55 ± 2.49 D and +0.17 ± 1.43 D, respectively, although the difference was not statistically significant (P = 0.120). Myopia was commoner in the laser-treated group (six eyes [27%] vs five eyes [9%], P = 0.047), and two eyes from two different infants (10%) from this group also developed high myopia (> -6.00 D). For hypermetropia and astigmatism, there were no statistically significant differences between the groups (all P > 0.05). High myopia was strongly related to the post-conceptual age when receiving laser therapy (P = 0.025). In the laser-treated group, two infants (9%) had amblyopia and one (5%) had exotropia at 2 years of age. None of the eyes developed structural retinal sequelae.Conclusion: Despite successful treatment of ROP, a significant number of laser-treated eyes developed myopia. This highlights the need for long-term refractive screening in these patients.

scholarly journals Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

2016 ◽  
Vol 46 ◽  
pp. 764-768
Author(s):  
Ahmet Murad HONDUR ◽  
Mehmet Özgür ÇUBUK ◽  
Zühal ÖZEN TUNAY ◽  
Hatice Tuba ATALAY ◽  
Özdemir ÖZDEMİR ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab

Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

2020 ◽  
pp. 163-168
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Peripheral Retina ◽  
Controlled Clinical Trial ◽  
Disease Development ◽  
Retinal Vessels ◽  
Randomized Controlled Clinical Trial ◽  
Zone Ii ◽  
Conventional Laser

The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a randomized, controlled clinical trial to determine whether intravitreal bevacizumab monotherapy was an effective therapy for treating zone I or zone II posterior stage 3+ (stage 3 with plus disease) retinopathy of prematurity (ROP). Intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels (with possible recurrence of ROP) continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina.

scholarly journals Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Hamid Riazi-esfahani ◽  
Alireza Mahmoudi ◽  
Mehdi Sanatkar ◽  
Afsar Dastjani Farahani ◽  
Fatemeh Bazvand
Keyword(s):  
Retinopathy Of Prematurity ◽  
Initial Treatment ◽  
Vitreous Body ◽  
Intravitreal Bevacizumab ◽  
Complete Regression ◽  
Recurrence Rates ◽  
Treatment Groups ◽  
The Difference

Abstract Background To evaluate the outcome of intravitreal bevacizumab (IVB) and aflibercept (IVA) injection for patients with retinopathy of prematurity (ROP). Methods In this single-center retrospective cohort, the recorded medical data of the infants who had been undergone intravitreal injection with either bevacizumab or aflibercept for type 1 ROP were reviewed. The infants were allocated into two groups. IVB group included patients who were treated with bevacizumab as initial treatment and the IVA group included patients who were treated with aflibercept as initial treatment. The rate and time of complete regression, as well as the recurrence rates, were compared between the groups. Results A total of 889 eyes of 453 infants were enrolled in the study. There were 865 eyes of 441 infants in the IVB group and 24 eyes of 12 infants in the IVA group. Follow-up time was 289 ± 257 days in the IVB group and 143 ± 25 days in the IVA group (p < 0.001). The difference in the ROP zone was not statistically significant between the 2 treatment groups (p = 0.328). All eyes in the IVA group showed initial regression of ROP after the intravitreal injections. These regressions were achieved in 830 (96.0%) eyes that were injected with IVB (p = 0.023). The median observed regression time was 10 days and 16 days in eyes treated with bevacizumab and aflibercept respectively. Recurrence was noted in 3.9% of eyes (34/865) in the IVB group and 58.3% of eyes (14/24) in the IVA group (p < 0.001). Conclusion While the regression rate in the IVA group was significantly higher than in the IVB group, the recurrence rate was significantly more in the IVA group, which may be attributed to differences in the pharmacokinetics of these drugs in the vitreous body.

Sign in / Sign up

Export Citation Format

Share Document